Milner R, Shaaban A, Kim H B, Fichter C, Flake A W
The Children's Institute for Surgical Science, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
J Surg Res. 1999 May 1;83(1):44-7. doi: 10.1006/jsre.1998.5558.
The primary barrier to clinical application of in utero hematopoietic stem cell (HSC) transplantation is limited donor cell engraftment. We hypothesized that limited engraftment was due to competition between host and donor cells for available niches. We reasoned that increased engraftment might be achieved by performing multiple transplants separated by brief intervals to allow time for formation of new niches. To test this we performed multiple transplants in a congenic combination to avoid confounding immunologic effects.
C57Pep3B (H2Kb, CD45.1) mice were used as donors of adult bone marrow and C57Bl/6 (H2Kb, CD45.2) mice were used as 14-day-gestation fetal recipients. All fetuses were injected intraperitoneally with 1 x 10(6) mononuclear cells. Boosted neonates were injected at Days 2, 4, and 7 of life with 5 x 10(6) cells. All animals were analyzed for donor cell engraftment by dual-color flow cytometry using CD45 and CD45.1 antigens. Results are reported as the mean +/- SD. Statistical analysis was performed using the two-tailed Student t test with P < 0.05 considered significant.
Postnatally boosted animals demonstrated significantly elevated levels of donor cell engraftment (3.30 +/- 0.8%; n = 8; P < 0.00001) when compared to the control animals (0.69 +/- 0.5%; n = 9) as determined by peripheral blood analysis at 6 weeks of age. This elevated level of engraftment was stable long term.
Our results demonstrate a significant increase in donor cell engraftment with postnatal booster injections after in utero transplantation. This supports the hypothesis that a limited number of niches may be a major component of the barrier to engraftment. It also suggests that postnatal booster injections may be a viable therapeutic strategy for improving donor cell engraftment after in utero HSC transplantation.
子宫内造血干细胞(HSC)移植临床应用的主要障碍是供体细胞植入受限。我们推测植入受限是由于宿主细胞与供体细胞竞争可用的龛位所致。我们推断,通过在短时间间隔内进行多次移植,以便有时间形成新的龛位,可能会增加植入率。为了验证这一点,我们采用同基因组合进行多次移植,以避免混淆免疫效应。
C57Pep3B(H2Kb,CD45.1)小鼠用作成年骨髓供体,C57Bl/6(H2Kb,CD45.2)小鼠用作妊娠14天的胎儿受体。所有胎儿均经腹腔注射1×10⁶个单核细胞。出生后接受强化注射的新生小鼠在出生后第2、4和7天分别注射5×10⁶个细胞。使用CD45和CD45.1抗原通过双色流式细胞术分析所有动物的供体细胞植入情况。结果以平均值±标准差表示。采用双侧Student t检验进行统计分析,P<0.05被认为具有统计学意义。
与对照组动物(0.69±0.5%;n = 9)相比,出生后接受强化注射的动物在6周龄时通过外周血分析确定的供体细胞植入水平显著升高(3.30±0.8%;n = 8;P<0.00001)。这种升高的植入水平长期稳定。
我们的结果表明,子宫内移植后进行出生后强化注射可显著提高供体细胞植入率。这支持了以下假设,即有限数量的龛位可能是植入障碍的主要组成部分。这也表明出生后强化注射可能是改善子宫内HSC移植后供体细胞植入的一种可行治疗策略。